| 초록 |
Despite numerous attempts, treating glomerulonephropathies has been all the more challenging and its guidelines had little variations in the past two decades.
Meanwhile, with the rapid development of scientific technology, there has been a remarkable progress in revealing pathogenesis and applying targeted therapies, especially in the field of oncology and rheumatology. Targeted therapy based on molecular diagnostics has not only improved the therapeutic outcomes but also alleviated toxicity and adverse effects. In recent years, there have been attempts to apply targeted medicines to treat glomerulonephropathies as well, some of which has shown promising results in clinical trials. In this session, I would like to briefly update recently revealed pathogeneses of glomerulonephropathies to date, and discuss the potential therapeutic options. |